HUTCHMED seeks FDA approval for Orpathys-Tagrisso lung cancer treatment
HCM•HUTCHMED submitted a US FDA application for Orpathys with Tagrisso to treat advanced MET-overexpressing or MET-amplified lung cancer after progression on EGFR-TKI therapy. Regulatory submissions in Europe and Japan are progressing as planned.
1. US application submitted
HUTCHMED submitted a US FDA application for Orpathys with Tagrisso in advanced MET-overexpressing or MET-amplified lung cancer following progression on EGFR-TKI therapy. The company said regulatory submissions in Europe and Japan are progressing as planned.
